Company
Re-Vana Therapeutics
Through innovative sustained-release therapeutics, we aim to resolve the treatment burden of frequent intravitreal injections and improve the quality of care for patients with sight-threatening diseases.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Belfast, Northern Ireland, United Kingdom
- Customers
- leading global pharmaceutical companies
- Legal name
- Re-Vana Therapeutics
- revanatx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 17 September 2026
About
We are developing and delivering photo-crosslinked, biodegradable ocular drug delivery systems engineered to provide 6 months + sustained release for a broad range of therapeutic modalities, including Biologics, Peptides, Large and Small Molecules
Funding snapshot
- Total raised
- $11.9MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series A, $11.9M2022-11-30
Funding rounds
- Series A
- $11.9M2022-11-30, Company stated
Products
- Other
- EyeLief
- Other
- OcuLief
Loading relationship preview